About Knight Therapeutics
Knight Therapeutics is a publicly listed company based in Montreal (Canada) founded in 2014. Marketing services for the biopharma sector are provided. It operates on a Reseller / Distribution and HealthTech model. The company has 745 employees. Its website knighttx.com draws about 14 thousand monthly visits. Knight Therapeutics offers products and services including Impavido and Specialty Pharmaceuticals. Its focus areas include Pharmaceuticals and Specialty Pharmaceuticals. Its legal entity is Knight Therapeutics Inc.
Company details
Knight Therapeutics Inc. is recognized as a leading pan-American specialty pharmaceutical company, excluding the US. Operations are conducted in Canada and Latin America, with a focus on distributing innovative and specialty pharmaceutical products. Solutions are provided to address various therapeutic needs across multiple countries, including Argentina, Brazil, and Mexico. The company is committed to building partnerships and expanding its presence in the healthcare sector.
- Headquarters Montreal, Canada
- Employees 745
- Stage Public
- SectorsHealthcare
- Phone•••• ••••
- Website knighttx.com
- Legal Name Knight Therapeutics, Inc.
- Annual Revenue$328.73 M (USD)21.22as on Dec 31, 2025
- Net Profit-$3.92 M (USD)-224.05as on Dec 31, 2025
- EBITDA$39.71 M (USD)-10.32as on Dec 31, 2025
- Employee Count745
Products & Services of Knight Therapeutics
Knight Therapeutics offers a comprehensive portfolio of products and services, including Impavido and Specialty Pharmaceuticals.
Impavido is provided for specific medical treatment needs.
Specialty pharmaceuticals are distributed across various therapeutic areas.
People of Knight Therapeutics
31 people are tracked at Knight Therapeutics (21 in leadership, 10 in team); the tracked headcount is 745.
| Name | Role | Group |
|---|---|---|
Ignacio Lugones | Sr. Corporate Director Fp&a | Leadership |
Amal Khouri | Chief Business Officer | Leadership |
Fernando Perez | Senior Finance Director Corporate | Leadership |
Bernardo dos Santos Irrazabal | Director Finance & Corp. Development | Leadership |
Hudson Santos | Global Director Strategic Produts | Leadership |
María Belén Salvo Guido | Corporate Finance Manager, Business Partner | Leadership |
Juan Francisco Perez Chavarria | CFO Nola | Leadership |
Juliana Alves | Global Senior Director, Alliance Management And PMO | Leadership |
Arvind Utchanah | Chief Financial Officer | Leadership |
Tatiana Cortes Montaña | Latam Brand Lead & Oncology Business Unit Head COL | Leadership |
Liliana Lucarino | Head Of Procurement | Leadership |
Leopoldo Bosano | VP Manufacturing & Operations | Leadership |
Mélanie Groleau | Vice President Medical And Clinical Affairs | Leadership |
Samira Sakhia | President And Chief Executive Officer | Leadership |
Denys Kurilko Us | Director Of Finance And Financial Reporting | Leadership |
Geneviève Larouche | Director, Global Pharmacovigilance And Medical Information | Leadership |
Corey C. Richardson | Director, Global Sales Operations | Leadership |
Susan Emblem | Global Vice President Human Resources | Leadership |
Francisco Fernández Dios | Marketing Director | Leadership |
Juan Ignacio Ezcurra | Director Finance - FPA | Leadership |
11 more people are available in the full profile.
Complete people profiles for Knight Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Knight Therapeutics
Knight Therapeutics is a publicly listed company on the TSX with ticker symbol GUD in Canada, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date29 Apr 2014
- Listed onTSX: GUD
- Listed entityKnight Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINCA4990531069
- Share price10.68 CAD (-1.39% on the day) · 2026-10-13
- Market capitalisation1,049,113,740.00 CAD
- Price to earnings71.2
- EPS (diluted, trailing year)0.15 CAD
- Volume (last session)93,745
Financials of Knight Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 450.1M CAD | -5.4M CAD | 54.4M CAD |
| 2024 | 371.3M CAD | 4.3M CAD | 60.6M CAD |
| 2023 | 328.2M CAD | -16.8M CAD | 56.8M CAD |
| 2022 | 293.6M CAD | -29.9M CAD | 46.0M CAD |
| 2021 | 243.5M CAD | 15.7M CAD | 37.2M CAD |
Detailed financial statements for Knight Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Web traffic of Knight Therapeutics
The website of Knight Therapeutics (knighttx.com) receives about 13.6K visits a month.
- Monthly visits13.6K
▲ 14.4% vs previous month
Websites whose visitors overlap most with Knight Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| cannara.ca | 100% | 5.1K | #3,869,175 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Knight Therapeutics
Complete news archive for Knight Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Knight Therapeutics
Knight Therapeutics was founded in 2014.
Knight Therapeutics is headquartered in Montreal, Canada. It is registered at Montreal, Quebec, Canada.
Knight Therapeutics has 745 employees.
Annual revenue of Knight Therapeutics is $328.73M as on Dec 31, 2025.
Knight Therapeutics Inc. is recognized as a leading pan-American specialty pharmaceutical company, excluding the US. Operations are conducted in Canada and Latin America, with a focus on distributing innovative and specialty pharmaceutical products. Solutions are provided to address various therapeutic needs across multiple countries, including Argentina, Brazil, and Mexico. The company is committed to building partnerships and expanding its presence in the healthcare sector.
Knight Therapeutics offers Impavido and Specialty Pharmaceuticals.
Yes, Knight Therapeutics is publicly traded on TSX under the ticker symbol GUD.
Knight Therapeutics operates through Knight Therapeutics Inc..